OncoMatch/Clinical Trials/NCT05686798
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
Is NCT05686798 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS) for malignant glioma of brain.
Treatment: Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS) — The primary goal of this Phase I study is to determine the maximum tolerated dose of oncolytic adenovirus mediated double suicide-gene therapy in combination with fractionated stereotactic radiosurgery in patients with recurrent high-grade astrocytoma undergoing resection.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Disease stage
Grade: high-grade
radiologic evidence of intracranial recurrence or progression of a previously diagnosed high-grade astrocytoma
Prior therapy
Must have received: radiation therapy
An interval of at least 3 months must have elapsed since the completion of the most recent course of radiation
Cannot have received: gene or virus therapy
No prior treatment of the tumor with gene or virus therapy
Cannot have received: immunotherapy
No prior treatment of the tumor with...immunotherapy
Cannot have received: brachytherapy
No prior treatment of the tumor with...brachytherapy
Cannot have received: polymer implant containing chemotherapeutic agents (Gliadel Wafer)
No prior treatment of the tumor with...implants of polymers containing chemotherapeutic agents (e.g. Gliadel Wafer)
Lab requirements
Blood counts
platelet count ≥ 100,000/μl; absolute neutrophil count ≥ 1,000/μl; hemoglobin > 10.0 g/dl
Kidney function
creatinine clearance ≥ 50 ml/min/m2
Liver function
bilirubin < 1.5 mg/dl; sgot and sgpt < 2.5 times upper limit of normal (uln)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Henry Ford Health System · Detroit, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05686798 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene or virus therapy, immunotherapy, brachytherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages